Latest Bare-metal stent Stories
ABBOTT PARK, Ill. and ST. PAUL, Minn., April 23, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) and St. Jude Medical (NYSE: STJ) today announced Choice Alliance, a multi-year joint initiative that provides mutual U.S. customers access to a robust portfolio of interventional cardiology, cardiac rhythm management, electrophysiology and intravascular imaging and diagnostic technologies. This enhanced alliance, which builds upon an existing agreement between the two companies that began in...
NATICK, Mass. and CHICAGO, March 26, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces its support of the HORIZONS II AMI clinical trial, which is designed to evaluate the safety and efficacy of the PROMUS Element(TM) Plus Everolimus-Eluting Platinum Chromium (PtCr) Coronary Stent compared to the OMEGA(TM) Platinum Chromium Bare-Metal Stent in patients experiencing an acute myocardial infarction (AMI), commonly referred to as a heart attack. The trial is...
NATICK, Mass., Feb. 22, 2012 /PRNewswire/ -- Boston Scientific Corporation's (NYSE: BSX) ION(TM) Paclitaxel-Eluting Platinum Chromium Coronary Stent System and TAXUS® Liberte® Paclitaxel-Eluting Coronary Stent System have received U.S. Food and Drug Administration (FDA) approval for use in patients experiencing an acute myocardial infarction (AMI), or heart attack. They are the only drug-eluting stent (DES) systems in the U.S. with an approved indication to treat patients with...
ALBANY, New York, February 8, 2012 /PRNewswire/ -- New Report Added in ResearchMoz Reports Database Global Drug Eluting (DES), Bare Metal (BMS) and Other Coronary Stents Market (2011 - 2016) [http://www.researchmoz.com/global-drug-eluting-des-bare-metal-bms-and-other-coronary-stents-market-2011-2016-report.html ] The coronary stents market has witnessed patterns of increasing market growth along with some declining phases in its course of span. The introduction of...
NEW YORK, November 22, 2011 /PRNewswire/ -- According to a new report published by Transparency Market Research ( http://www.transparencymarketresearch.com) "Global Drug Eluting (DES), Bare Metal (BMS) and Other Coronary Stents Market (2011 - 2016) [http://www.transparencymarketresearch.com/coronary-stents-market.html ] "Global Coronary Stents market is estimated to be USD 6,013million in 2011 and expected to reach USD 8,292million in 2016 at a CAGR of 6.6% over the period...
NATICK, Mass. and SAN FRANCISCO, Nov. 11, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) reports results from the EVOLVE First Human Use trial demonstrating the non-inferiority of the SYNERGY(TM) Everolimus-Eluting Stent System compared to the PROMUS Element(TM) Everolimus-Eluting Stent System in treating de novo coronary artery lesions. The trial provided 30-day clinical and six-month angiographic primary endpoint data evaluating the safety and effectiveness of the...
DURHAM, N.C., Nov. 8, 2011 /PRNewswire/ -- Micell Technologies, Inc. today announced the release of preliminary data from the first-in-human clinical study of the MiStent(® )Sirolimus Drug Eluting Coronary Stent System (MiStent DES), a thin-strut drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating designed for controlled drug release. Four, six and eight month data from the DESSOLVE I trial were presented at the Transcatheter Cardiovascular Therapeutics Conference...
NATICK, Mass. and SAN FRANCISCO, Nov. 8, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) reports positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the ION(TM) (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Stent System versus prior-generation paclitaxel-eluting stents. Results were presented today by PERSEUS clinical program Principal Investigators Louis Cannon, M.D., of the Cardiac...
DURHAM, N.C., Nov. 2, 2011 /PRNewswire/ -- Micell Technologies, Inc. today announced that it has completed a preliminary analysis of data from the first-in-human clinical study, DESSOLVE I, of the MiStent® Sirolimus Drug Eluting Coronary Stent System, a thin drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating formulation that is designed for controlled drug release. Four, six and eight month data will be presented at the Transcatheter Cardiovascular Therapeutics...
NATICK, Mass., Nov. 1, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) releases the schedule of its major events and product-related clinical research for the Cardiovascular Research Foundation's (CRF) 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, scheduled for November 7 - 11 in San Francisco. TCT is designed to provide new insights for physicians who treat patients with cardiovascular disease and other vascular health issues. "Among the...
